Slynd is under clinical development by Insud Pharma and currently in Phase III for Endometriosis. According to GlobalData, Phase III drugs for Endometriosis have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Slynd’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Slynd overview
Drospirenone (Slynd, Slinda, Lyzbet) is a synthetic spironolactone analogue with anti-mineralocorticoid activity. It is formulated as film coated tablets and coated tablets, tablets for oral route of administration. Drospirenone is indicated for use by females of reproductive potential to prevent pregnancy.
Drospirenone is under development as the hormonal contraceptive in female patients, endometriosis. It is administered orally as a Film-coated tablet. The drug candidate is a synthetic progestogen which acts by targeting the progesterone receptor.
Insud Pharma overview
Insud Pharma (Insud ) is a pharmaceutical company, that conducts research, development, manufacture, sales and marketing of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), branded pharmaceuticals and biopharmaceutical products. It also offers intermediate steroids, injectable and oral solid dosages, oral contraceptive pills (OCPs) and placebos, monoclonal antibodies and vaccines and other biological formulations for various therapeutic areas. Insud also provides contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services through business units Chemo, Exeltis and mAbxience. The company operates its manufacturing facility and research and development sites and commercial offices in Europe, the Americas, Asia, and Africa. Insud Pharma is headquartered in Madrid, Spain.
For a complete picture of Slynd’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
